Literature DB >> 9354589

Regulation of CYP4A1 and peroxisome proliferator-activated receptor alpha expression by interleukin-1beta, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes.

J H Parmentier1, H Schohn, M Bronner, L Ferrari, A M Batt, M Dauça, P Kremers.   

Abstract

The CYP4A1 isoenzyme induced in rodents by peroxisome proliferators is known to be repressed at a pretranslational level by interferon. Interleukin-1beta (IL-1beta) also reduces CYP4A1-related 12-laurate hydroxylase activity in cultured fetal rat hepatocytes after induction by clofibric acid. In this fetal hepatocyte model, IL-1beta and interleukin-6 (IL-6) were tested for their ability to reduce 12-laurate hydroxylase activity, CYP4A1 apoprotein content, and the CYP4A1 mRNA level. IL-1beta and IL-6 strongly diminished CYP4A1 activity and apoprotein and mRNA levels in a dose- and time-dependent manner. CYP4A1 expression is thus down-regulated at a pretranslational level by these cytokines. As it has been shown that the peroxisome proliferator-activated receptor alpha (PPAR alpha) mediates the induction of the CYP4A1 gene by a peroxisome proliferator, the capacity of IL-1beta or IL-6 to modulate the PPAR alpha mRNA level was tested. It was found that IL-1beta and IL-6 both repress the induction of PPAR alpha expression exerted by the combined action of clofibric acid and dexamethasone. However, even at the highest concentration (10 ng/mL) tested for both cytokines, IL-1beta as well as IL-6 failed to abolish the induction of CYP4A1 by dexamethasone. The mechanism of the protective effect of the synthetic glucocorticoid on CYP4A1 repression by interleukins is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354589     DOI: 10.1016/s0006-2952(97)00256-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection.

Authors:  Jun Lei; Meghan S Vermillion; Bei Jia; Han Xie; Li Xie; Michael W McLane; Jeanne S Sheffield; Andrew Pekosz; Amanda Brown; Sabra L Klein; Irina Burd
Journal:  JCI Insight       Date:  2019-02-28

Review 2.  Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death.

Authors:  A N Kong; S Mandlekar; R Yu; W Lei; A Fasanmande
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

Review 3.  Lipid Use and Misuse by the Heart.

Authors:  P Christian Schulze; Konstantinos Drosatos; Ira J Goldberg
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

4.  Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: the role of cytokines.

Authors:  A M Bleau; M C Levitchi; H Maurice; P du Souich
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

Review 5.  Cardiac lipotoxicity: molecular pathways and therapeutic implications.

Authors:  Konstantinos Drosatos; P Christian Schulze
Journal:  Curr Heart Fail Rep       Date:  2013-06

6.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30

Review 7.  The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

Authors:  Charikleia Kalliora; Konstantinos Drosatos
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

8.  A clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.

Authors:  Graham Jang; Allegra Kaufman; Edward Lee; Lisa Hamilton; Shauna Hutton; Ogo Egbuna; Desmond Padhi
Journal:  Pharmacol Res Perspect       Date:  2014-03-13

Review 9.  PPARs: Protectors or Opponents of Myocardial Function?

Authors:  Christine J Pol; Melissa Lieu; Konstantinos Drosatos
Journal:  PPAR Res       Date:  2015-12-02       Impact factor: 4.964

10.  Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats.

Authors:  Wei Wang; Chuang Wang; Xiao-Qin Ding; Ying Pan; Ting-Ting Gu; Ming-Xing Wang; Yang-Liu Liu; Fu-Meng Wang; Shui-Juan Wang; Ling-Dong Kong
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.